Heavy episodic drinking and HIV disclosure by HIV treatment status among People with HIV in IeDEA Cameroon.
Alcohol
Antiretroviral therapy
HIV
Social support
Sub-Saharan Africa
Journal
The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
13
05
2021
revised:
11
08
2021
accepted:
16
08
2021
pubmed:
18
9
2021
medline:
27
1
2022
entrez:
17
9
2021
Statut:
ppublish
Résumé
Heavy alcohol use is common among people with HIV (PWH), leading to sub-optimal HIV care outcomes. Yet, heavy episodic drinking (HED) is not routinely addressed within most HIV clinics in sub-Saharan Africa. HIV disclosure may provide social support, potentially reducing HED to cope with HIV. We examined the prevalence of HED and HIV disclosure by antiretroviral treatment (ART) status among PWH receiving HIV care in Cameroon. We analyzed routine HIV clinical data augmented with systematic alcohol use data among adult PWH receiving HIV care in three regional hospitals from January 2016 to March 2020. Recent HED prevalence was examined across PWH by ART status: those not on ART, recent ART initiators (ART initiation ≤30 days prior), and ART users (ART initiation >30 days prior); and by gender. We used log-binomial regression to estimate prevalence differences (PD) between HIV disclosure and recent HED by ART status. Among 12,517 PWH in care, 16.4% (95%CI: 15.7, 17.0) reported recent HED. HED was reported among 21.2% (95%CI: 16.0, 26.3) of those not on ART, 24.5% (95%CI: 23.1, 26.0) of recent ART initiators, and 12.9% (95%CI: 12.2, 13.6) of ART users. Regardless of ART status, men were more likely than women to report HED. Those who disclosed HIV status had a lower HED prevalence than those who had not disclosed (aPD: -0.07; 95%CI: -0.10, -0.05) and not modified by gender. The prevalence of recent HED was high among PWH in care. HED prevalence was highest among men and recent ART initiators. Longitudinal analyses should explore how HIV disclosure may support PWH in reducing or abstaining from HED through social support. Systematic HED screening and referral to care should be included in routine HIV clinical care, particularly for men, to improve engagement in the HIV care continuum in Cameroon.
Sections du résumé
BACKGROUND
Heavy alcohol use is common among people with HIV (PWH), leading to sub-optimal HIV care outcomes. Yet, heavy episodic drinking (HED) is not routinely addressed within most HIV clinics in sub-Saharan Africa. HIV disclosure may provide social support, potentially reducing HED to cope with HIV. We examined the prevalence of HED and HIV disclosure by antiretroviral treatment (ART) status among PWH receiving HIV care in Cameroon.
METHODS
We analyzed routine HIV clinical data augmented with systematic alcohol use data among adult PWH receiving HIV care in three regional hospitals from January 2016 to March 2020. Recent HED prevalence was examined across PWH by ART status: those not on ART, recent ART initiators (ART initiation ≤30 days prior), and ART users (ART initiation >30 days prior); and by gender. We used log-binomial regression to estimate prevalence differences (PD) between HIV disclosure and recent HED by ART status.
RESULTS
Among 12,517 PWH in care, 16.4% (95%CI: 15.7, 17.0) reported recent HED. HED was reported among 21.2% (95%CI: 16.0, 26.3) of those not on ART, 24.5% (95%CI: 23.1, 26.0) of recent ART initiators, and 12.9% (95%CI: 12.2, 13.6) of ART users. Regardless of ART status, men were more likely than women to report HED. Those who disclosed HIV status had a lower HED prevalence than those who had not disclosed (aPD: -0.07; 95%CI: -0.10, -0.05) and not modified by gender.
CONCLUSION
The prevalence of recent HED was high among PWH in care. HED prevalence was highest among men and recent ART initiators. Longitudinal analyses should explore how HIV disclosure may support PWH in reducing or abstaining from HED through social support. Systematic HED screening and referral to care should be included in routine HIV clinical care, particularly for men, to improve engagement in the HIV care continuum in Cameroon.
Identifiants
pubmed: 34534821
pii: S0955-3959(21)00336-4
doi: 10.1016/j.drugpo.2021.103431
pmc: PMC8671318
mid: NIHMS1740659
pii:
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
103431Subventions
Organisme : NIAID NIH HHS
ID : U01 AI096299
Pays : United States
Informations de copyright
Copyright © 2021. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declarations of Interest The authors have no conflicts of interests to declare.
Références
Afr J AIDS Res. 2016 Dec;15(4):367-376
pubmed: 27974021
AIDS Care. 2017 Jul;29(7):838-845
pubmed: 28024412
BMJ Glob Health. 2016 Dec 30;1(4):e000125
pubmed: 28588979
J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):171-8
pubmed: 22820808
J Int AIDS Soc. 2021 Jun;24(6):e25672
pubmed: 34152663
J Pers Assess. 2014;96(1):103-12
pubmed: 24090236
Drug Alcohol Depend. 2012 Jan 1;120(1-3):113-8
pubmed: 21820252
Int J Environ Res Public Health. 2016 Jan 27;13(2):166
pubmed: 26828506
Med Care. 2003 Nov;41(11):1284-92
pubmed: 14583691
J Stud Alcohol Drugs. 2009 Jul;70(4):516-27
pubmed: 19515291
J Acquir Immune Defic Syndr. 2019 Dec 15;82(5):443-451
pubmed: 31567551
AIDS Behav. 2017 Nov;21(Suppl 2):144-154
pubmed: 28710711
PLoS One. 2020 Aug 27;15(8):e0237772
pubmed: 32853246
AIDS Care. 2021 Sep;33(9):1133-1138
pubmed: 32613851
Addiction. 2016 Feb;111(2):272-9
pubmed: 26381193
J Gen Intern Med. 2009 Feb;24(2):189-97
pubmed: 19031037
Drug Alcohol Depend. 2008 Apr 1;94(1-3):234-45
pubmed: 18215474
Lancet HIV. 2021 Jun;8(6):e353-e362
pubmed: 33932330
Ann Intern Med. 2004 Apr 6;140(7):554-6
pubmed: 15068984
Alcohol Clin Exp Res. 2016 Aug;40(8):1779-87
pubmed: 27426424
J Virus Erad. 2018 Nov 15;4(Suppl 2):26-32
pubmed: 30515311
BMC Int Health Hum Rights. 2007 Aug 03;7:6
pubmed: 17683541
BMC Public Health. 2011 Mar 10;11:160
pubmed: 21392398
PLoS One. 2014 Oct 28;9(10):e109447
pubmed: 25350001
Curr HIV/AIDS Rep. 2011 Sep;8(3):172-80
pubmed: 21713433
Alcohol Clin Exp Res. 2016 Feb;40(2):256-9
pubmed: 26842244
Drug Alcohol Depend. 2010 Dec 1;112(3):178-93
pubmed: 20705402
J Addict Med. 2013 Jul-Aug;7(4):264-70
pubmed: 23666322
AIDS Behav. 2021 Apr;25(4):1306-1322
pubmed: 33206263
BMC Public Health. 2017 Jul 4;17(Suppl 3):548
pubmed: 28832283
J Int AIDS Soc. 2019 Jul;22(7):e25331
pubmed: 31623428
Int J Epidemiol. 2012 Oct;41(5):1256-64
pubmed: 21593078
J Int AIDS Soc. 2013 Nov 13;16(3 Suppl 2):18636
pubmed: 24242256
Afr J Psychiatry (Johannesbg). 2012 Sep;15(5):346-51
pubmed: 23044889
AIDS Behav. 2018 May;22(5):1652-1661
pubmed: 28975510
PLoS One. 2020 Oct 23;15(10):e0240654
pubmed: 33095784
PLoS One. 2017 Dec 27;12(12):e0189820
pubmed: 29281681
AIDS Behav. 2020 Jun;24(6):1727-1742
pubmed: 31673913
J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):280-9
pubmed: 19521248
BMC Public Health. 2016 Jul 08;16:529
pubmed: 27390926
AIDS Behav. 2019 Jun;23(6):1656-1667
pubmed: 30560484
BMC Public Health. 2019 May 28;19(1):651
pubmed: 31138239
BMC Public Health. 2018 Nov 7;18(Suppl 3):1216
pubmed: 30400910
Implement Sci Commun. 2020;1(1):68
pubmed: 32835226
J Stud Alcohol Drugs. 2017 Jan;78(1):88-96
pubmed: 27936368
Ann Behav Med. 2018 Aug 16;52(9):762-772
pubmed: 30124756